

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. 'Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Lawrence B. Bugaisky Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro\* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich' George S. Bardmesser Daniel A. Klein' Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller' LuAnne M. DeSantis John J. Figueroa Ann E. Summerfield Tiera S. Coston Aric W. Ledford' Jessica L. Parezo

Timothy A. Doyle\*
Gaby L. Longsworth\*
Nicole D. Dretar\*
Ted J. Ebersole
Jyoti C. Iyer\*
Registered Patent Ag
Karen R. Markowicz
Nancy J. Leith

Registered Patent Agents •
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Matthew J. Dowd
Aaron L. Schwartz
Katina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Eric D. Hayes Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

<u>Of Counsel</u> Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

\*Admitted only in Maryland \* Admitted only in Virginia •Practice Limited to Federal Agencies

August 6, 2004

WRITER'S DIRECT NUMBER: (202) 772-8589 INTERNET ADDRESS: LARRYB@SKGF.COM

Art Unit 1646

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/672,020; Filed: September 29, 2000

For: Polypeptide Derivatives of Parathyroid Hormone (PTH)

Inventors:

GARDELLA et al.

Our Ref:

0609.4820002/LBB/M-G

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Reply Under 37 C.F.R. § 1.111; and
- 2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Laure B. Bugusty

Lawrence B. Bugaisky Attorney for Applicants

Registration No. 35,086

Enclosures

296669\_1.DOC

Sterne, Kessler, Goldstein & Fox P.L.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

1646 1=121



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gardella et al.

Appl. No. 09/672,020

Filed: September 29, 2000

For:

**Polypeptide Derivatives of** 

Parathyroid Hormone (PTH)

Confirmation No.: 2982

Art Unit:

1646

Examiner:

Murphy, J. F.

Atty. Docket: 0609.4820002/LBB/M-G

## **Reply Under 37 C.F.R. § 1.111**

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated **June 25, 2004**, Applicants submit the following Amendment and Reply. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper.

However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a),

and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.